China Resources Boya Bio-pharmaceutical Group , Ltd. (300294.SZ) has a profit margin of -11.73%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
China Resources Boya Bio-pharmaceutical Group , Ltd.'s profit margin stands at -11.73% as of September 2026. That compares with 16.66% in the prior-year period — down 170.4% year over year. That is below the Healthcare sector average of 17.63%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
China Resources Boya Bio-pharmaceutical Group , Ltd. reported -11.73% in profit margin versus 16.66% a year earlier — a 170.4% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
China Resources Boya Bio-pharmaceutical Group , Ltd. sits lower the Healthcare benchmark (17.63%) with a profit margin of -11.73%. That is roughly 166.5% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A profit margin of -11.73% for China Resources Boya Bio-pharmaceutical Group , Ltd. means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how China Resources Boya Bio-pharmaceutical Group , Ltd.'s profit margin evolved across reporting periods, while the comparison chart places 300294.SZ next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.